What is Entia?
Founded in 2015 and headquartered in the United Kingdom, Entia operates at the intersection of advanced engineering and clinical diagnostics. The company specializes in developing sophisticated medical technology designed to simplify and improve the accessibility of blood tests, effectively bringing laboratory-grade diagnostics closer to the patient. By focusing on user-centric design and high-precision hardware, Entia addresses the critical need for decentralized testing solutions that reduce the burden on traditional healthcare infrastructure. Its market position is defined by a commitment to deeptech innovation, ensuring that complex diagnostic procedures are both reliable and scalable for diverse clinical environments.
How much funding has Entia raised?
Entia has raised a total of $33.4M across 3 funding rounds:
Angel/Seed
$1.4M
Unspecified
$12M
Series A
$20M
Angel/Seed (2018): $1.4M with participation from Sussex Place Ventures
Unspecified (2021): $12M led by Parkwalk Advisors, BGF, and Sussex Place Ventures
Series A (2023): $20M supported by BGF
Key Investors in Entia
BGF
BGF is a prominent UK-based investment firm that serves as a primary source of growth capital for small and mid-sized enterprises across diverse economic sectors.
Parkwalk Advisors
Parkwalk Advisors is a specialized investor focused on commercializing university spinouts, providing essential expertise and funding to deeptech ventures emerging from academic research.
Sussex Place Ventures
Associated with the London Business School, Sussex Place Ventures is an early-stage VC firm that supports entrepreneurs building patent-protectable deep technology and enterprise software.
What's next for Entia?
With the successful closure of its latest funding round, Entia is poised to enter a transformative phase of its corporate lifecycle. The strategic deployment of these funds will likely focus on scaling manufacturing capabilities, expanding clinical validation studies, and strengthening its commercial footprint across international markets. As the company matures, the focus will shift toward integrating its diagnostic platforms into broader healthcare networks, thereby solidifying its role as a key provider of point-of-care testing solutions. Investors and industry observers will be closely monitoring Entia's ability to navigate the regulatory landscape while maintaining its momentum in the competitive healthtech sector.
See full Entia company page
